Novocure announced that its Phase 3 PANOVA-3 trial showed a significant improvement in median overall survival for patients with advanced pancreatic cancer using Tumor Treating Fields therapy, achieving 16.20 months compared to 14.16 months for the control group, with plans to seek regulatory approval based on these results.